Skip to main content
. Author manuscript; available in PMC: 2022 Apr 1.
Published in final edited form as: J Rheumatol. 2020 Nov 1;48(4):504–512. doi: 10.3899/jrheum.200673

Table 4.

Associations Between FGF-21 Values and Functional Outcomes

Effect on Outcome at Baseline Effect on Rate of Change of Outcome
β (95% CI) P N β (95% CI) P N
HAQ
 FGF-21 (Continuous) 0.068 (−0.073, 0.21) 0.34 111 0.025 (−0.015, 0.064) 0.22 83
 FGF-21 in Top Quartile 0.34 (0.039, 0.63) 0.03 111 0.034 (−0.045, 0.11) 0.29 83
SPPB
 FGF-21 (Continuous) −0.47 (−1.04, 0.10) 0.11 68 −0.14 (−0.37, 0.088) 0.22 49
 FGF-21 in Top Quartile −1.68 (−2.94, −0.41) 0.01 68 −0.57 (−1.04, −0.091) 0.02 49

Legend: Models include adjustments for age, gender, visceral fat area, current smoking, and methotrexate use (all at baseline). β coefficients represent differences associated with a 1 SD higher FGF-21 level at baseline.